NexCure, Inc.
PrivateLast Round
Series A
Mar 5, 2026
Est. Valuation
$985.7M
Total Funding Raised
$329M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
NexCure, Inc. operates in Healthcare & Life Sciences and is based in Boston, Massachusetts. Its latest recorded funding round was a Series A round in March 2026.
NexCure, Inc. is a healthcare company that partners with health systems to build and operate outpatient treatment centers for CAR-T and other advanced therapies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Subscription SaaS
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NexCure, Inc. Comparables
Compare NexCure, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Cencora | 62% | |
| The Oncology Institute, Inc. | 61% | |
| American Oncology Network Inc | 61% |
For institutional investors. Book with your work email.
NexCure, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Mar 5, 2026 | ||||
| Private Placement | Nov 17, 2025 | ||||
| Follow-on Offering | Nov 19, 2019 | ||||
| IPO | May 8, 2019 | ||||
| Series B | Nov 13, 2018 | ||||
Series A | Jan 6, 2016 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
NexCure, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Bay City Capital | Series B |
| Surveyor Capital | Series B |
| RA Capital Management | Series A |
| Hillhouse Investment | Series B |
| Taiho Ventures | Series B |
| OrbiMed | Series A, Series B |
| Ikarian Capital | Private Placement |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 5, 2026
$19M round led by RA Capital Management.
For institutional investors. Book with your work email.
NexCure, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about NexCure, Inc.'s valuation, stock price, and market status.
Is NexCure, Inc. a public or private company?
NexCure, Inc. is a private company.
What is the current stock price of NexCure, Inc.?
NexCure, Inc. is a private company, so its shares have no public market price. Caplight tracks NexCure, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is NexCure, Inc. worth (valuation)?
NexCure, Inc.'s valuation is estimated at $985.7M based on funding round data.
Can I buy NexCure, Inc. stock?
NexCure, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was NexCure, Inc.'s last funding round?
NexCure, Inc.'s most recent funding round was Series A on March 5, 2026.
Who are the main investors in NexCure, Inc.?
Key investors in NexCure, Inc. include RA Capital Management, Hillhouse Investment, Ikarian Capital, Morgan Stanley, Bank of America Merrill Lynch.
Will NexCure, Inc. IPO soon?
No public IPO plans have been announced for NexCure, Inc..
How can I track NexCure, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in NexCure, Inc.'s shares on secondary markets.